01 10Sandostatin
Main Therapeutic Indication : Oncology
Currency : USD
2020 Revenue in Millions : 1,439
2019 Revenue in Millions : 1,585
Growth (%) : -9
Main Therapeutic Indication : Oncology
Currency : USD
2021 Revenue in Millions : 1,413
2020 Revenue in Millions : 1,439
Growth (%) : -2
Main Therapeutic Indication : Oncology
Currency : USD
2022 Revenue in Millions : 1,238
2021 Revenue in Millions : 1,413
Growth (%) : -12
Main Therapeutic Indication : Oncology
Currency : USD
2023 Revenue in Millions : 1,314
2022 Revenue in Millions : 1,238
Growth (%) : 6
Main Therapeutic Indication : Oncology
Currency : USD
2014 Revenue in Millions : 3.80%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Oncology
Currency : USD
2015 Revenue in Millions : 1,650
2014 Revenue in Millions : 1,630
Growth (%) : -1%
Main Therapeutic Indication : Oncology
Currency : USD
2016 Revenue in Millions : 1,646
2015 Revenue in Millions : 1,630
Growth (%) : 1
Main Therapeutic Indication : Oncology
Currency : USD
2017 Revenue in Millions : 1,612
2016 Revenue in Millions : 1,646
Growth (%) : -2
Main Therapeutic Indication : Oncology
Currency : USD
2018 Revenue in Millions : 1,587
2017 Revenue in Millions : 1,612
Growth (%) : -2%
Main Therapeutic Indication : Oncology
Currency : USD
2019 Revenue in Millions : 1,585
2018 Revenue in Millions : 1,587
Growth (%) : 0
LOOKING FOR A SUPPLIER?